HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
2 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
INTS2
integrator complex subunit 2
Chromosome 17 · 17q23.2
NCBI Gene: 57508Ensembl: ENSG00000108506.15HGNC: HGNC:29241UniProt: Q9H0H0
62PubMed Papers
20Diseases
0Drugs
0Pathogenic Variants
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
INTAC complexsnRNA processingregulation of transcription elongation by RNA polymerase IIintegrator complexneurodegenerative diseaseglomerulonephritisexstrophy-epispadias complexmyotonic syndrome
✦AI Summary

INTS2 is a component of the integrator complex, a multiprotein complex that terminates RNA polymerase II transcription in promoter-proximal regions 12. The complex provides quality control during transcription elongation by catalyzing CTD dephosphorylation, degrading nascent RNA transcripts, and promoting Pol II release 12. INTS2 also participates in terminating non-coding Pol II transcripts including snRNAs, eRNAs, and lncRNAs 3, and mediates cytoplasmic dynein recruitment to the nuclear envelope 4. Based on limited published evidence, INTS2 has been identified as a candidate gene in autosomal recessive Parkinson's disease 5.

Sources cited
1
INTS2 is a component of the integrator complex that terminates Pol II transcription and catalyzes CTD dephosphorylation
PMID: 33243860
2
INTS2 participates in quality checkpoint during transcription elongation through CTD dephosphorylation and nascent RNA degradation
PMID: 38570683
3
INTS2-containing integrator complex terminates synthesis of non-coding Pol II transcripts including snRNAs and lncRNAs
PMID: 16239144
4
INTS2 mediates recruitment of cytoplasmic dynein to the nuclear envelope
PMID: 23904267
5
INTS2 identified as a candidate autosomal recessive gene in Parkinson's disease families
PMID: 40959972
Disease Associationsⓘ20
neurodegenerative diseaseOpen Targets
0.35Weak
glomerulonephritisOpen Targets
0.22Weak
exstrophy-epispadias complexOpen Targets
0.12Weak
myotonic syndromeOpen Targets
0.10Weak
Parkinson diseaseOpen Targets
0.09Suggestive
coffee consumptionOpen Targets
0.08Suggestive
immune system diseaseOpen Targets
0.07Suggestive
liver diseaseOpen Targets
0.06Suggestive
mathematical abilityOpen Targets
0.03Suggestive
esophageal carcinomaOpen Targets
0.02Suggestive
Kaposi's sarcomaOpen Targets
0.02Suggestive
ovarian dysfunctionOpen Targets
0.02Suggestive
device complicationOpen Targets
0.02Suggestive
breast neoplasmOpen Targets
0.01Suggestive
breast cancerOpen Targets
0.01Suggestive
neoplasmOpen Targets
0.01Suggestive
colorectal cancerOpen Targets
0.01Suggestive
breast carcinomaOpen Targets
0.01Suggestive
endometrial cancerOpen Targets
0.01Suggestive
melanomaOpen Targets
0.01Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Related Genes
INTS14Protein interaction100%POLR2BProtein interaction100%POLR2LProtein interaction100%POLR2KProtein interaction100%POLR2EProtein interaction100%POLR2DProtein interaction100%
Tissue Expression6 tissues
Heart
100%
Bone Marrow
85%
Brain
73%
Ovary
57%
Liver
48%
Lung
46%
Gene Interaction Network
Click a node to explore
INTS2INTS14POLR2BPOLR2LPOLR2KPOLR2EPOLR2D
PROTEIN STRUCTURE
Preparing viewer…
PDB8RC4 · 3.10 Å · EM
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.49Moderately Constrained
pLIⓘ
0.98Intolerant
Observed/Expected LoF0.36 [0.26–0.49]
RankingsWhere INTS2 stands among ~20K protein-coding genes
  • #7,470of 20,598
    Most Researched62
  • #2,898of 17,882
    Most Constrained (LOEUF)0.49 · top quartile
Genes detectedINTS2
Sources retrieved2 papers
Response time—
📄 Sources
2
1
Expanding the Autosomal Recessive Gene Spectrum of Parkinson's Disease: A Study within the CPD10KGP.
PMID: 40959972
Mov Disord · 2025
1.00
2
Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites.
PMID: 26811494
Oncotarget · 2016
0.50